Lyell Immunopharma, Inc. (NASDAQ:LYEL) Chief Operating Officer Stephen J. Hill executed a sale of 89 shares on May 11, 2026, to satisfy tax withholding obligations from vested restricted stock units. The transaction, valued at $1,683, occurred at a weighted average price of $18.92 per share, significantly above the stock's recent trading range of $13.55. This sale reduces Hill's direct holdings to 17,894 shares, inclusive of 188 shares acquired under the company's 2021 Employee Stock Purchase Plan on May 18, 2026. The transaction follows a period of significant stock depreciation, with LYEL shares declining approximately 58% over the preceding six months. Concurrently, Lyell Immunopharma reported positive developments in its clinical pipeline, including a 97% manufacturing success rate for rondecabtagene autoleucel in treating relapsed or refractory large B-cell lymphoma and a reduction in gastrointestinal side effects in its colorectal cancer program. Analyst firms H.C. Wainwright and Citizens reiterated positive ratings on the stock, citing clinical progress and financial positioning.
The sale was made to cover tax withholding obligations arising from the settlement of vested restricted stock units. Following this transaction, Mr. Hill directly holds 17,894 shares of Lyell Immunopharma common stock. This total includes 188 shares acquired on May 18, 2026, under the Issuer’s 2021 Employee Stock Purchase Plan. The transaction occurred well above the current stock price of $13.55, reflecting the company’s sharp decline over recent months. The stock has fallen roughly 58% over the past six months, according to InvestingPro data, which tracks comprehensive metrics for over 135,000 global securities.
In other recent news, Lyell Immunopharma presented safety and translational data from its Phase 1/2 clinical trial of rondecabtagene autoleucel, treating 108 patients with relapsed or refractory large B-cell lymphoma. The company reported a manufacturing success rate of 97% for these patients. Meanwhile, Lyell’s colorectal cancer program saw a reduction in side effects, with gastrointestinal prophylaxis decreasing the occurrence of Grade 2 or higher diarrhea or colitis from 55% to 10%. This led to an amendment in the ongoing Phase 1 trial, potentially paving the way for expansion into a Phase 2 trial. H.C. Wainwright reiterated a Buy rating and set a $45 price target on Lyell shares, acknowledging the updated safety data. The firm addressed previous concerns about cytokine release syndrome and other side effects in the colorectal cancer program. Citizens also maintained a Market Outperform rating with a $34 price target, citing the company’s clinical progress and financial position. These developments reflect Lyell’s ongoing efforts in improving treatment outcomes and addressing safety concerns in its trials.